Pyxis Oncology, Inc.

Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.

PYXS | NDAQ

Overview

Corporate Details

ISIN(s):: US7473241013
LEI:
Country:: United States of America
Address:: 321 HARRISON AVENUE, 2118 BOSTON
Website:: https://pyxisoncology.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing an arsenal of next-generation therapeutics for difficult-to-treat cancers. The company has assembled a differentiated portfolio of clinical assets centered on two key platforms: Antibody-Drug Conjugates (ADCs) and Immuno-Oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for safer and more effective treatments. The company's IO approaches, including monoclonal antibody (mAb) immunotherapies, aim to mobilize the patient's immune system to attack cancer. Pyxis Oncology develops its product candidates as both monotherapies and in combination with other therapies to improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Pyxis Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pyxis Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Pyxis Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
AGIOS PHARMACEUTICALS, INC. Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.	United States of America	AGIO
AIM ImmunoTech Inc. Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.	United States of America	AIM
AKANDA CORP. Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.	United States of America	AKAN
Akari Therapeutics Plc A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.	United States of America	AKTX
Akebia Therapeutics, Inc. Developing and commercializing novel, FDA-approved therapeutics for kidney disease.	United States of America	AKBA
Akero Therapeutics, Inc. A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.	United States of America	AKRO
Alaunos Therapeutics, Inc. Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.	United States of America	TCRT
Aldeyra Therapeutics, Inc. Biotech developing therapies for ocular and systemic immune-mediated inflammation.	United States of America	ALDX
Alector, Inc. Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.	United States of America	ALEC
Aligos Therapeutics, Inc. Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.	United States of America	ALGS